scholarly journals 833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer

2020 ◽  
Vol 31 ◽  
pp. S626-S627
Author(s):  
D.M. O'Malley ◽  
D.L. Richardson ◽  
I.B. Vergote ◽  
L. Gilbert ◽  
C. Castro ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Folate Receptor ◽  
Antibody Drug Conjugate ◽  
Folate Receptor Alpha ◽  
Receptor Alpha ◽  
Drug Conjugate ◽  
Platinum Sensitive ◽  
Antibody Drug

Safety Profile of Mirvetuximab Soravtansine, a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Patients with Recurrent Ovarian Cancer

2020 ◽  
Vol 156 (3) ◽  
pp. e15-e16
Author(s):  
Kathleen G. Essel ◽  
Lainie P. Martin ◽  
David M. O’Malley ◽  
Ursula Matulonis ◽  
Jason A. Konner ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Safety Profile ◽  
Folate Receptor ◽  
Recurrent Ovarian Cancer ◽  
Antibody Drug Conjugate ◽  
Folate Receptor Alpha ◽  
Receptor Alpha ◽  
Drug Conjugate ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document